Merck vs Pfizer (MRK vs PFE)
Pfizer trades at 40.1x earnings vs 139.2x for Merck; Merck grows sales faster (+4.7% vs -0.4%). Margins, debt and dividend, Nov 2026.
Quick answer
On today's data (November 19, 2026): Pfizer looks cheaper on P/E: 40.1x against 139.2x for Merck. Merck grows faster: sales +4.7% against -0.4% for Pfizer in the latest quarter. Pfizer has the better net margin: 6.3% against 3.6% for Merck.
This is a snapshot of the numbers, not a recommendation to buy or sell.
Your first analysis is free with a free account, no card.
Short answer
On P/E as of November 19, 2026, Merck is the more expensive of the two: it trades at 139.2x its annual earnings against 40.1x for Pfizer. Merck & Co. reports two segments. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. What helps read that gap: Merck sales +4.7% against -0.4% for Pfizer in the latest quarter; net margin 3.6% against 6.3%; net debt for Merck: 1.5x EBITDA against 2.0x EBITDA. A higher P/E is not by itself a buy or a sell signal: it is a snapshot of today.
Merck (MRK) and Pfizer (PFE) compete in healthcare and pharma. Here are Merck and Pfizer side by side with their real figures as of November 19, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Merck or Pfizer.
Merck vs Pfizer: the figures
| Figure | Merck | Pfizer |
|---|---|---|
| Share price | $137.78 (November 18, 2026) | $28.06 (November 18, 2026) |
| Market cap | $339.7 billion | $159.9 billion |
| P/E (TTM) | 139.2x | 40.1x |
| Forward P/E | 15.4x | 9.5x |
| Revenue growth (quarter) | +4.7% | -0.4% |
| Net margin (TTM) | 3.6% | 6.3% |
| Net debt / EBITDA | 1.5x | 2.0x |
| Dividend yield | 2.55% | 6.13% |
| Beta | 0.12 | 0.30 |
Merck and Pfizer figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 19, 2026; N/A means that Merck or Pfizer figure is not available, and we never estimate it.
3 key differences between Merck and Pfizer
- Valuation: Merck trades at 139.2x its annual earnings and Pfizer at 40.1x; the market pays more for each dollar of Merck profit, usually because it expects more growth.
- Dividend: Pfizer yields 6.13% at today's price and Merck yields 2.55%.
- Growth: Merck grew sales +4.7% year on year in its latest quarter, against -0.4% for Pfizer.
Merck or Pfizer: which fits your profile
- If you want growth: Merck is growing faster today, with sales +4.7% against -0.4% for Pfizer and also trades on a higher P/E (139.2x against 40.1x). Investors who prioritise growth usually accept more volatility; the P/E only shows what you pay today for each unit of the last 12 months' earnings.
- If you want income (dividends): Pfizer pays the higher dividend relative to its price.
- If you prefer caution: Merck has less debt relative to its profit, which usually gives more room in a bad year.
- If price is what matters most to you: Pfizer trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.
Neither Merck nor Pfizer wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
Verdict: Merck or Pfizer?
Of the 6 comparable figures in the table, Merck stands out on 3 (sales growth, less debt over EBITDA and lower volatility (beta)) and Pfizer stands out on 3 (net margin, lower P/E and dividend yield). That does not name a winner between Merck and Pfizer: the table is a snapshot of today, not a forecast.
Keep reading free.
Create your free account to continue reading “Merck vs Pfizer (MRK vs PFE)”.
No card required
Merck vs Pfizer by dimension
Strategy
Merck operates in healthcare and pharma and Pfizer in healthcare and pharma, so they only fight for the same customer when the sector overlaps. By stock-market size, Merck is the larger of the two.
Products and AI
Merck and Pfizer sell different things: Merck & Co. And for Pfizer: Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev.
Margins
Pfizer is more profitable: it keeps 6.3 of every 100 it sells, against 3.6 for Merck.
Valuation
Merck trades at the higher P/E (139.2x against 40.1x for Pfizer). A higher P/E is only justified if earnings grow faster.
Risks
Pfizer is the more volatile: beta 0.30 against 0.12 for Merck.
Competitors
Other companies investors compare Merck and Pfizer with: Intuitive Surgical, Johnson & Johnson, Thermo Fisher, UnitedHealth. Intuitive Surgical · Johnson & Johnson · Thermo Fisher · UnitedHealth
How Merck and Pfizer make money
Merck (MRK)
Merck & Co. reports two segments. Pharmaceutical, by far the larger, sells Keytruda, its top cancer immunotherapy, the HPV vaccine Gardasil, Winrevair, Bridion and diabetes drugs like Januvia. Animal Health sells medicines and vaccines for pets and livestock, including the Bravecto flea and tick treatment. Full Merck analysis.
Pfizer (PFE)
Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. The U.S. is its biggest market. Full Pfizer analysis.
Frequently asked questions: Merck vs Pfizer
What is the difference between Merck and Pfizer?
Merck & Co. Pfizer sells medicines and vaccines grouped into Primary Care, which includes the blood thinner Eliquis shared with Bristol Myers, Prevnar and Comirnaty vaccines and the antiviral Paxlovid; Specialty Care, led by Vyndaqel; and Oncology, with Ibrance, Xtandi and Seagen drugs like Padcev. Both are in healthcare and pharma. As of November 19, 2026: P/E 139.2 vs 40.1; net margin 4% vs 6% (Merck vs Pfizer).
Is Merck or Pfizer the better stock?
Choosing between Merck and Pfizer depends on what you are looking for. Merck is growing faster right now, and Pfizer trades on the lower P/E. Fintols does not tell you whether to buy Merck or Pfizer: it shows you the differences so you can decide.
Which pays a higher dividend, Merck or Pfizer?
As of November 19, 2026, Pfizer yields 6.13% and Merck yields 2.55%. Also check how much of their profit Merck and Pfizer pay out: if it is more than they earn, it cannot last.
Which is more expensive, Merck or Pfizer?
On P/E, Merck (139.2x) is more expensive than Pfizer (40.1x) as of November 19, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.
Which is more profitable, Merck or Pfizer?
On net margin, Pfizer (6.3%) keeps more of every 100 it sells than Merck (3.6%), as of November 19, 2026.
Which has more debt, Merck or Pfizer?
As of November 19, 2026, Pfizer owes 2.0x its EBITDA and Merck owes 1.5x its EBITDA (net debt over EBITDA).
Can I own both Merck and Pfizer?
Yes. Many people spread their money across several companies, such as Merck and Pfizer, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Merck or Pfizer.
To go deeper: Does Merck pay a dividend? and Does Pfizer pay a dividend?.
Related comparisons for Merck and Pfizer
More companies like Merck and Pfizer: healthcare and pharma stocks. Educational content about Merck and Pfizer, not investment advice.
Full analyses: Merck and Pfizer. Machine-readable summary: llms.txt.
Your first analysis is free with a free account, no card.
Your own analysis of Merck or Pfizer.
Create a free account and run your first full analysis in a minute. No card needed.
- How it makes money
- Valuation scenarios
- What could go wrong
First full analysis free · No card